News

Telehealth company Hims & Hers reported first-quarter results late Monday that beat Wall Street estimates. But parts of the ...
Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.
Hims & Hers reports 111% YoY sales growth & 70%+ gross margin. Discover their growth potential, risks, & why it's a Buy recommendation.
The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 20.2% in the afternoon session after the company reported ...
Hims & Hers Health, Inc.'s subscriber growth, Novo Nordisk partnership, and FDA pill approval could boost financials. Click ...
Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...
Palantir Technologies raises its full-year outlook but the stock falls, Ford suspends guidance because of uncertainty over ...
Hims & Hers Health Inc has reiterated its 2025 revenue forecast after posting better-than-expected sales for the first ...